73 related articles for article (PubMed ID: 29119842)
1. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
[TBL] [Abstract][Full Text] [Related]
2. Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma.
Fulati W; Ma J; Wu M; Qian W; Chen P; Hu Y; Chen M; Xu Y; Huang Z; Zhang H; Xie Y; Shen L
Front Immunol; 2024; 15():1382189. PubMed ID: 38799461
[TBL] [Abstract][Full Text] [Related]
3. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Advani RH; Skrypets T; Civallero M; Spinner MA; Manni M; Kim WS; Shustov AR; Horwitz SM; Hitz F; Cabrera ME; Dlouhy I; Vassallo J; Pileri SA; Inghirami G; Montoto S; Vitolo U; Radford J; Vose JM; Federico M
Blood; 2021 Jul; 138(3):213-220. PubMed ID: 34292324
[TBL] [Abstract][Full Text] [Related]
5. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India.
Nemani S; Korula A; Agrawal B; Kavitha ML; Manipadam MT; Sigamani E; George B; Srivastava A; Viswabandya A; Mathews V
Indian J Med Res; 2018 May; 147(5):464-470. PubMed ID: 30082570
[TBL] [Abstract][Full Text] [Related]
7. THE ROLE OF RADIATION THERAPY IN THE TREATMENT OF PTCL-NOS.
Kriachok I; Aleksyk O; Tytorenko I; Bushuieva M; Moroz Y
Probl Radiac Med Radiobiol; 2023 Dec; 28():504-512. PubMed ID: 38155144
[TBL] [Abstract][Full Text] [Related]
8. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients.
Chen NC; Chang H; Kuo MC; Lin TL; Shih LY; Chuang WY; Kao HW
J Formos Med Assoc; 2024 Feb; 123(2):188-197. PubMed ID: 37558588
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
[TBL] [Abstract][Full Text] [Related]
10. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
Kim SJ; Jo JC; Yoon DH; Yang DH; Yoon SE; Lee GW; Kong JH; Park Y; Kang KW; Lee HS; Oh SY; Shin HJ; Lee WS; Choi YS; Jeong SH; Kim MK; Kang HJ; Yi JH; Lim SN; Yhim HY; Do YR; Yun HJ; Eom HS; Lee MH; Suh C; Kim WS
Front Oncol; 2023; 13():1230629. PubMed ID: 37675232
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.
Brink M; Huisman F; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem MJ; Bohmer LH; Woei-A-Jin FJSH; Visser OJ; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Huls GA; Vermaat JSP; Plattel WJ; Nijland M
Blood Adv; 2024 May; ():. PubMed ID: 38739705
[TBL] [Abstract][Full Text] [Related]
12. Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma.
Moskowitz AJ
J Oncol Pract; 2019 Mar; 15(3):137-143. PubMed ID: 30861367
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT; Ganesan N; Epstein-Peterson ZD; Moskowitz AJ; Stuver RN; Maccaro CR; Galasso N; Chang T; Khan N; Aypar U; Lewis NE; Zelenetz AD; Palomba ML; Matasar MJ; Noy A; Hamilton AM; Hamlin P; Caron PC; Straus DJ; Intlekofer AM; Lee Batlevi C; Kumar A; Owens CN; Sauter CS; Falchi L; Lue JK; Vardhana SA; Salles G; Dogan A; Schultz ND; Arcila ME; Horwitz SM
Blood Adv; 2023 Sep; 7(17):5172-5186. PubMed ID: 37078708
[TBL] [Abstract][Full Text] [Related]
14. 25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas.
Shen HR; Tang J; Li WY; Liang JH; Li Y; Wu JZ; Wang L; Li JY; Gao R; Yin H; Xu W
Ann Hematol; 2024 Feb; 103(2):565-574. PubMed ID: 37951853
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract][Full Text] [Related]
16. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Hapgood G; Civallero M; Stepanishyna Y; Vose J; Cabrera ME; Advani RH; Pileri SA; Manni M; Horwitz SM; Foss FM; Hitz F; Radford J; Dlouhy I; Chiattone C; Kim WS; Skrypets T; Nagler A; Trotman J; Luminari S; Federico M
Blood Adv; 2023 Sep; 7(17):5047-5054. PubMed ID: 37163360
[TBL] [Abstract][Full Text] [Related]
17. Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
Girard L; Koh YJ; Koh LP; Chee YL; Chan HL; Lee J; de Mel S; Poon LM; Samuel M
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38443704
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
Fardella E; Zanirato G; Magni M; Caldarelli N; Chiappella A; Dodero A; Ljevar S; Orsucci L; Re A; Usai SV; Stefoni V; Castellino C; Rossi FG; Pinto A; Carniti C; Corradini P
Br J Haematol; 2024 May; 204(5):1752-1756. PubMed ID: 38176400
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
Abouyabis AN; Shenoy PJ; Sinha R; Flowers CR; Lechowicz MJ
ISRN Hematol; 2011; 2011():623924. PubMed ID: 22084700
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
